TW
VRTX icon

Traveka Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Traveka Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$201K Buy
+404
New +$179K 0.07% 192
2025
Q2 		– Sell
-422
Closed -$205K – 157
2025
Q1 		$205K Buy
+422
New +$197K 0.11% 138

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Traveka Wealth's VRTX Position: Q2 2026 in Review

Traveka Wealth opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 404 shares worth $201K. The stake represents 0.07% of the portfolio and ranks #192 among its holdings. This is a return to the name: Traveka Wealth previously reported a position in VRTX as recently as Q1 2025.

Traveka Wealth first reported a position in VRTX in Q1 2025 and has held it in 2 quarters since. The position peaked at $205K in Q1 2025. 484 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Traveka Wealth held 404 shares of Vertex Pharmaceuticals worth $201K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Traveka Wealth position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.07% of Traveka Wealth's portfolio in Q2 2026, its #192 holding.
  • Traveka Wealth first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 2 quarters since.
  • Traveka Wealth's Vertex Pharmaceuticals position peaked at $205K in Q1 2025.
  • 484 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Traveka Wealth's 13F filing for Q2 2026, filed 21 Jul 2026.